Chrysafi Pavlina, Jani Chinmay T, Lotz Margaret, Al Omari Omar, Singh Harpreet, Stafford Katherine, Agarwal Lipisha, Rupal Arashdeep, Dar Abdul Qadir, Dangelo Abby, Lam Prudence
Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA.
Department of Medicine, Harvard Medical School, Boston, MA 02129, USA.
Cancers (Basel). 2023 Dec 8;15(24):5762. doi: 10.3390/cancers15245762.
Hereditary Breast and Ovarian Cancer (HBOC) and Lynch Syndrome (LS) are the most common inherited cancer syndromes identified with genetic testing. Testing, though, commonly reveals variants of uncertain significance (VUSs). This is a retrospective observational study designed to determine the prevalence of pathogenic mutations and VUSs in patients tested for HBOC and/or LS and to explore the characteristics of the VUS population. Patients 18-80 years old that met NCCN criteria for HBOC and/or LS genetic screening were tested between 2006 and 2020 at Mount Auburn Hospital in Cambridge, Massachusetts. A total of 663 patients were included in the study, with a mean age of 50 years old and 90% being females. Pathogenic mutations were identified in 12.5% and VUSs in 28.3%. VUS prevalence was associated with race (-value = 0.019), being particularly higher in Asian populations. Patients with a personal history of breast cancer or family history of breast or ovarian cancer were more likely to have a VUS (personal breast: OR: 1.55; CI: 1.08-2.25; family breast: OR: 1.68; CI: 1.08-2.60, family ovarian OR: 2.29; CI: 1.04-5.45). In conclusion, VUSs appear to be detected in almost one third patients tested for cancer genetic syndromes, and thus future work is warranted to determine their significance in cancer development.
遗传性乳腺癌和卵巢癌(HBOC)以及林奇综合征(LS)是通过基因检测确定的最常见的遗传性癌症综合征。然而,检测通常会发现意义未明的变异(VUS)。这是一项回顾性观察研究,旨在确定接受HBOC和/或LS检测的患者中致病突变和VUS的患病率,并探索VUS人群的特征。2006年至2020年期间,在马萨诸塞州剑桥市的奥本山医院对符合HBOC和/或LS基因筛查NCCN标准的18至80岁患者进行了检测。共有663名患者纳入研究,平均年龄为50岁,90%为女性。发现致病突变的比例为12.5%,VUS的比例为28.3%。VUS患病率与种族相关(P值=0.019),在亚洲人群中尤其更高。有个人乳腺癌病史或乳腺癌或卵巢癌家族史的患者更有可能有VUS(个人乳腺癌:比值比:1.55;可信区间:1.08 - 2.25;家族性乳腺癌:比值比:1.68;可信区间:1.08 - 2.60,家族性卵巢癌比值比:2.29;可信区间:1.04 - 5.45)。总之,在接受癌症遗传综合征检测的患者中,几乎三分之一检测出VUS,因此有必要开展进一步研究以确定它们在癌症发生中的意义。